Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients With EGFR Wild-Type Non-Small-Cell Lung Cancer: The Never-Ending Story

被引：13

作者：

Gelsomino, Francesco ^{[1
]}

Agustoni, Francesco ^{[1
]}

Niger, Monica ^{[1
]}

Valota, Marika ^{[1
]}

Haspinger, Eva R. ^{[1
]}

机构：

[1] Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, I-20133 Milan, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 26期

关键词：

PHASE-III TRIAL; PLATINUM-BASED CHEMOTHERAPY; DOUBLE-BLIND; OPEN-LABEL; MAINTENANCE THERAPY; 1ST-LINE ERLOTINIB; 2ND-LINE TREATMENT; GEFITINIB; MULTICENTER; PLACEBO;

D O I：

10.1200/JCO.2013.50.2617

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3291 / 3293

页数：3

共 50 条

[41] Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
O'Leary, Connor
Gasper, Harry
Sahin, Katherine B.
Tang, Ming
Kulasinghe, Arutha
Adams, Mark N.
Richard, Derek J.
O'Byrne, Ken J.
PHARMACEUTICALS, 2020, 13 (10) : 1 - 16
[42] MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer
Camidge, D. Ross
Davies, Kurtis D.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (11) : 855 - +
[43] Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
Moriya, Tetsuji
Hamaji, Masatsugu
Yoshizawa, Akihiko
Miyata, Ryo
Noguchi, Misa
Tamari, Shigeyuki
Chiba, Naohisa
Miyamoto, Hideaki
Toyazaki, Toshiya
Tanaka, Satona
Yamada, Yoshito
Yutaka, Yojiro
Nakajima, Daisuke
Ohsumi, Akihiro
Menju, Toshi
Date, Hiroshi
INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2022, 34 (03) : 416 - 423
[44] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non-Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor A Meta-analysis
Lee, June-Koo
Hahn, Seokyung
Kim, Dong-Wan
Suh, Koung Jin
Keam, Bhumsuk
Kim, Tae Min
Lee, Se-Hoon
Heo, Dae Seog
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (14): : 1430 - 1437
[45] The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs
Sheng, Zhixin
Zhang, Yanxia
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (04): : 362 - 369
[46] Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer
Su, Kang-Yi
Chen, Hsuan-Yu
Li, Ker-Chau
Kuo, Min-Liang
Yang, James Chih-Hsin
Chan, Wing-Kai
Ho, Bing-Ching
Chang, Gee-Chen
Shih, Jin-Yuan
Yu, Sung-Liang
Yang, Pan-Chyr
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) : 433 - 440
[47] Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma
Yoneda, Ken Y.
Hardin, Kimberly A.
Gandara, David R.
Shelton, David K.
CLINICAL LUNG CANCER, 2006, 8 : S31 - S35
[48] Role of erlotinib in the treatment of advanced non-small-cell lung cancer patients with EGFR wild-type tumors
Braun, Eduardo
Bonomi, Philip
LUNG CANCER MANAGEMENT, 2014, 3 (01) : 101 - 116
[49] Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy
Wu, Di
Duan, Chongyang
Wu, Fenfang
Chen, Liyong
Chen, Size
ONCOTARGET, 2017, 8 (39) : 66491 - 66503
[50] Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Kujtan, Lara
Subramanian, Janakiraman
EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (07) : 547 - 559

← 1 2 3 4 5 →